Abstract
Kyowa currently ranks 42nd of all researched-based companies in terms of
pharmaceutical sales. This report provides a full review of the company's
activities together with sales forecasts for key products to 2010.
Kyowa has terminated, in March 2005, its Japanese marketing agreement with
Janssen (J&J) for the oral antifungal, Itrizole (itraconazole). The move
leaves Kyowa with just three key products. The loss of Itrizole gives Kyowa a
huge short term headache as it accounted for 19.1% of total pharmaceutical
sales in fiscal 2005.
The company is concentrating its core business in pharmaceuticals and has
divested or restructured many of its non core food and chemical interests.
R&D Pipeline Overview
Kyowa has highlighted three candidate drugs as potential growth drivers for
the future:
- KW-6002 is a novel compound that is indicated for Parkinson's
disease. It is currently being developed in Europe, Canada and the US where it
is anticipated to be filed in 2006.
- KW-7158 differs from existing anticholinergic drugs in that it is
effective on peripheral sensory nerves in the bladder. The development of
KW-7158 indicates a move into a new therapeutic area for Kyowa, urology, with
the company citing the large market potential for this field, both
domestically and abroad.
- KW-2871 is a monoclonal antibody in early-stage development. It has
been shown to be effective against melanoma cells. The company is optimistic
for this compound and is investing in its overseas development.
Major Products Forecast to 2010
- Coniel (Cardiovascular)
- Allelock (Anti-allergenic)
- Celtect (Anti-allergenic)
- Durotep (CNS)
- Depakene (CNS)
- Adriacin/Farmorubicin (Anticancer)
- 5-FU (Anticancer)
- Nauzelin (Gastrointestinal)
- Neu-up (Blood & Fluid)
| 
View Cart
